I-Abiraterone CAS:154229-19-3

I-Abiraterone isetyenziswa kakhulu kwi-oncology ukulawula umhlaza we-prostate onganyangekiyo yi-metastatic castration (mCRPC). Njengomthinteli onamandla we-androgen biosynthesis, ijolise kwi-enzyme i-CYP17A1, ebalulekileyo kwimveliso ye-testosterone kunye nezinye ii-androgens. Ngokuthintela le enzyme, i-abiraterone ithintela ukuveliswa kwe-androgen zombini kwi-testes nakwi-tumor ngokwayo, ngaloo ndlela inciphisa amanqanaba e-androgens akhuthaza ukukhula komhlaza we-prostate. Ngokwezonyango, i-abiraterone inikwa ngomlomo kunye ne-prednisone okanye i-prednisolone ukunciphisa iziphumo ebezingalindelekanga. Olu hlobo lonyango lubonakalise ukusebenza kakuhle ekuphuculeni amazinga okusinda ngokubanzi kunye nokulibazisa ukuqhubela phambili kwesifo kwizigulane ezinomhlaza we-prostate ophambili eziye zafumana unyango lwe-androgen deprivation (ADT) ngaphambili. Ngaphezu koko, impembelelo yonyango ye-abiraterone idlula ngaphaya kwe-mCRPC. Uphando oluqhubekayo luhlola amandla ayo kumanqanaba okuqala omhlaza we-prostate kunye nokudibanisa nezinye iindlela zonyango ezifana ne-chemotherapy kunye nonyango olutsha olujoliswe kuyo. Indlela esebenza ngayo kunye neenzuzo zeklinikhi ziyaqhubeka nokuphandwa kwiimvavanyo ezahlukeneyo zeklinikhi ukuze kuphuculwe iziphumo zonyango kunye nokhathalelo lwezigulane. Ngamafutshane, i-abiraterone imele inqanaba elibalulekileyo kunyango lomhlaza, ingakumbi kulawulo lomhlaza we-prostate. Amandla ayo okuphazamisa ukuveliswa kwe-androgen anika indlela ejolise kuyo yokunyanga iithumba ezibuthathaka kwiihomoni, enika izigulane ixesha elide lokusinda kunye nomgangatho wobomi ophucukileyo. Ukuqhubela phambili okuqhubekayo kunye nezifundo zeklinikhi zigxininisa indima yayo ebalulekileyo ekuphuhliseni amaqhinga okunyanga umhlaza, zithembisa iindlela ezintsha zokhathalelo lwe-oncology lomntu ngamnye.